Our Big Idea: Imagine The End of Herpes as We Know It
Our mission is to prove Maxwell's patented "peptoid" virucidal drug class is safe in humans. This world-first drug class irreversibly inactivates humanity's top threat - highly infectious pandemic viruses including the Herpes Virus. One in three people in the developed world test as infected with the Herpes Virus which has been shown to drive chronic syndromes like cold sores, eye infections, brain infections, and reproductive infections. Maxwell's novel and patented anti-infectives have been shown by multiple independent labs (including Stanford, NYU and others) to be rapid killers of the worst drug-resistant pathogens. These preclinical lab tests show Maxwell peptoids are highly selective for viruses over human cells, are biostable, effective at low doses, and rapidly and irreversibly inactivate viruses. The irreversibly nature of the treatment paired with our preclinical data showing safety in human tissues make it a potential game changing therapeutic. We are in preclinical stage now, preparing for human trials.